RPRX
Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology · US
$67.30
−0.40%Margins
Gross margin
87.3%
EBITDA margin
59.2%
EBIT margin
59.8%
Net margin
25.7%
FCF margin
113.1%
9.8%
Return on equity
3.5%
Return on assets
10.1%
Return on invested capital
0.13x
Asset turnover
$3.0B
Cash from operations
$1.22
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026